Detalles de la búsqueda
1.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Int J Cancer
; 146(7): 1917-1929, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31330065
2.
Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model.
Eur J Haematol
; 96(1): 72-7, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25819739
3.
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
Am J Hematol
; 91(11): 1090-1095, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27465919
4.
Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis.
Blood
; 131(3): 365-368, 2018 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-29084773
5.
Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis.
Ann Hematol
; 97(10): 2005-2008, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29740683
6.
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.
J Immunother
; 46(1): 22-26, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36472582
7.
Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.
Am J Hematol
; 92(6): E91-E93, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28240788
8.
Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia.
Br J Haematol
; 175(5): 983-985, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-26728120
9.
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Sci Rep
; 11(1): 13770, 2021 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34215766
10.
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
J Exp Clin Cancer Res
; 39(1): 279, 2020 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33302999
11.
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Leuk Res
; 33(1): 162-5, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18556064
12.
Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia.
Eur J Haematol
; 83(3): 208-14, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19459926
13.
The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.
Leuk Lymphoma
; 60(7): 1644-1649, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30516079
14.
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Cancer Biol Ther
; 20(2): 192-200, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30403909
15.
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.
Leuk Res
; 31(11): 1575-8, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17485110
16.
Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Haematologica
; 92(10): 1367-74, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17768114
17.
Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease.
Leuk Lymphoma
; 47(6): 1034-40, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16840194
18.
Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis.
Clin Lymphoma Myeloma Leuk
; 15(3): e55-60, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25445470
19.
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).
Int J Hematol
; 100(3): 290-5, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25064370
20.
Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines.
Expert Rev Hematol
; 7(5): 691-5, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25174547